Oxaloacetate, a natural energy-cycle molecule sold as a heat-stabilized dietary supplement, is promoted as a way to mimic the effects of eating less. Human findings are modest and come from patients, not healthy people: fewer mood symptoms before menstruation and mixed results for fatigue after viral illness. Short-term use appears well tolerated, but long-term safety is unknown, and the case for longevity use in healthy adults remains uncertain. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting glucose | 75–90 mg/dL | Detect glucose lowering |
| HbA1c | 4.8–5.4% | Longer-term glucose trend |
| Fasting insulin | 2–6 µIU/mL | Insulin sensitivity |
| ALT | 10–25 U/L | Liver safety |
| AST | 10–25 U/L | Liver safety; oxaloacetate-handling enzyme |
| eGFR | Above 90 mL/min/1.73 m² | Kidney clearance |
| Plasma oxaloacetate | No established target; track change from own baseline | Absorption check |
| Chalder Fatigue Questionnaire | No established target; track at least 25% reduction from own baseline | Fatigue response |
Cadence: Baseline before starting; fasting glucose weekly for the first 4 weeks when combined with glucose-lowering drugs; full panel and fatigue score repeated at 6–12 weeks; then every 6–12 months with continued use